Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMEMBER: Empiric TB Treatment in Advanced HIV
NCT01380080Phase 4Completed
- Start
- Oct 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, randomised, open-label trial of rifampicin, isoniazid, pyrazinamide and ethambutol in Tuberculosis (TB) (2 arms). Primary endpoint: Cumulative Probability of Death or Unknown Vital Status at 24 weeks. Started Oct 2011; status: completed.
02
Drugs
rifampicinisoniazidpyrazinamideethambutol
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01380080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380080.